1. Home
  2. ALXO vs NEN Comparison

ALXO vs NEN Comparison

Compare ALXO & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.99

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$52.08

Market Cap

197.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
NEN
Founded
2015
1977
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
205.9M
197.0M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
ALXO
NEN
Price
$1.99
$52.08
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
941.1K
1.2K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
2.71%
EPS Growth
26.36
N/A
EPS
N/A
N/A
Revenue
N/A
$89,196,544.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$19.68
Revenue Growth
N/A
10.76
52 Week Low
$0.96
$52.08
52 Week High
$2.66
$73.50

Technical Indicators

Market Signals
Indicator
ALXO
NEN
Relative Strength Index (RSI) 49.51 40.86
Support Level $1.93 N/A
Resistance Level $2.21 $60.90
Average True Range (ATR) 0.12 0.42
MACD -0.00 -0.05
Stochastic Oscillator 38.72 10.29

Price Performance

Historical Comparison
ALXO
NEN

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: